Status:
COMPLETED
A Study in Older Subjects to Evaluate the Safety and Ability of Andexanet Alfa to Reverse the Anticoagulation Effect of Apixaban
Lead Sponsor:
Portola Pharmaceuticals
Conditions:
Bleeding
Eligibility:
All Genders
50-75 years
Phase:
PHASE3
Brief Summary
The purpose of this stuy is to evaluate the ability of Andexanet Alfa to reverse the anticoagulation effect of Apixaban.
Eligibility Criteria
Inclusion
- Reasonably healthy men and women aged 50 to 75
Exclusion
- History of abnormal bleeding, active bleeding or risk factors for bleeding
- History of thrombosis or risk factors for thrombosis
- History of adult asthma or use of inhaled medications
Key Trial Info
Start Date :
March 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2015
Estimated Enrollment :
68 Patients enrolled
Trial Details
Trial ID
NCT02207725
Start Date
March 1 2014
End Date
September 1 2015
Last Update
August 8 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Celerion
Tempe, Arizona, United States, 85283